Assuming that this is in the treatment naïve scenario, we have a lot of options in this case. The patient could be considered single agent immunotherapy or chemo-immunotherapy or clinical trials for KRAS G12C. While we need more prospective data on this topic, I still look at the co-mutations (...

For initial standard therapy in PD-L1 high KRAS G12C mutated NSCLC, the preferred treatment option is immune checkpoint inhibitor-based regimen. Evidence to support pembrolizumab monotherapy is based on KN024 study. However, patients with bulky tumor burden/visceral metastasis, high NLR may benefit ...

I think it's important to take in both patient factors and tumor characteristics in this setting to make the best therapeutic decision. I will often evaluate disease burden in terms of symptoms, along with the overall fitness of the patient to determine if adding chemotherapy to single agent PD-1 is...